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Introduction: Up to 40% of patients seen in a cough clinic have unexplained chronic cough.
The long term outcome of these patients is uncertain.
Objective: To determine the long-term outcome in patients diagnosed with unexplained
chronic cough.
Methods: We have performed a longitudinal study of symptoms, airway inflammation and
spirometry in a cohort of patients with unexplained chronic cough diagnosed over 7 years
ago. Cough was assessed using a 100 mm visual analogue scale (VAS). At the first and final visit
cough reflex sensitivity was assessed as the concentration of inhaled capsaicin at which the
volunteer coughed 2 (C2) and 5 times (C5).
Results: We identified 42 patients (32 females) with unexplained chronic cough who had been as-
sessed at least 7 years previously and agreed to a further assessment. The mean (SD) duration of
cough was 11.5 (4.5) years at the time of their final assessment. Nine patients (21%) had organ
specific autoimmune disease and twenty (48%) had a peripheral blood lymphopaenia. Six (14%)
patients had complete resolution of symptoms and 11 (26%) had a significant>10 mm improvement
in their cough VAS during follow up. Longitudinal spirometry data was available in 30 patients. The
median rate of FEV1 declinewas 44ml/year and four (13%) patients developed a post-bronchodilator
forced expiratory volume in 1 s (FEV1)/forced vital capacity of less than 0.7. FEV1 declinewas similar
in patientswith persistent cough and thosewhose cough improved. Noother independent predictors
of FEV1 decline were identified. There were no independent predictors of improvement in cough.
Conclusions: Cough persists over time in the majority of patients with unexplained chronic cough.
Patients have an increased rate of decline in FEV1 and a significant minority develop fixed airflow
obstruction.
ª 2012 Elsevier Ltd. All rights reserved.16 2502373.
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Long term outcome of patients with unexplained chronic cough 409Introduction assessment for the presence of organ-specific autoanti-Cough is an important symptom, responsible for consider-
able impairment of quality of life1 and accounting for
a large proportion of both primary and secondary care
referrals.2,3 Chronic cough, defined as a cough lasting
longer than 8 weeks, can be ascribed to a specific cause in
60e80% of patients.3 The remainder have unexplained
chronic cough and suffer impairment of quality of life,
equivalent in some domains to that seen in severe asthma
and COPD.1 Unexplained chronic cough is a challenge for
the respiratory physician as there are no satisfactory
treatments and almost nothing is known about the long-
term prognosis. More definitive information on the natural
history of unexplained chronic cough is needed both to
guide the management of patients in clinic and also to
direct further research.
We conducted a longitudinal observational study to
investigate the natural history of unexplained chronic
cough diagnosed at our institution over 7 years ago.
Methods
We identified all patients attending a specialist cough clinic
and diagnosed with unexplained chronic cough at Glenfield
Hospital between January 1998 and December 2001.
Unexplained chronic cough was defined as a cough lasting
greater than 8 weeks, with normal spirometry [forced
expiratory volume in 1 s (FEV1) >80% of predicted and
FEV1/forced vital capacity (FVC) ratio of >70%], a provoc-
ative concentration of methocholine required to cause
a 20% fall in FEV1 (PC20) of >8 mg/ml, a normal induced
sputum eosinophil count (<3%) and a normal high resolution
computed tomography (HRCT) scan of the thorax. Subjects
had failed treatment trials with asthma treatment,
a proton pump inhibitor and a nasal steroid spray as per
British Thoracic Society guidelines.4 The study was
approved by Leicestershire, Northamptonshire and Rutland
Ethics committee and all patients provided written
informed consent before inclusion.
Study measurements
Spirometry was performed with a Vitalograph spirometer
(Vitalograph, Buckinghamshire, UK) as the best of at least 3
successive readings within 100 ml. A capsaicin cough chal-
lenge was then performed. Subjects inhaled a single vital
capacity breath of 10 mL of 0.9% saline solution followed by
doubling concentrations of capsaicin from 0.49 mM/L every
1 min. Coughs were counted for 30 s following each inha-
lation. The counting of coughs was aided by a sound
recording device. The investigation was stopped when
500 mM/L solution was inhaled or when the subject coughed
5 times or more. The concentration of capsaicin required to
make the subject cough 2 (C2) and 5 (C5) times was
calculated by the linear interpolation of the log-dose
response curve.5 Sputum was induced using nebulised
hypertonic saline and processed for cell differential count
using the sputum selection protocol as described before.6
At the first visit patients had a full blood count and a fullbodies was done as patients were participants in an earlier
case-control study.7 The following autoantibodies were
measured: antinuclear (in house indirect immunofluores-
cence); rheumatoid factor (nephelometry, Dade Behring
BNII protein analyser; UK); islet cell (in house indirect
immunofluorescence); adrenal (indirect immunofluores-
cence; Biodiagnostics Limited, Worcestershire, UK); pari-
etal (in house indirect immunofluorescence); endomysial
(indirect immunofluorescence, Binding Site Limited, Bir-
mingham, UK); and thyroid peroxidase (fluorescent enzyme
linked immunosorbent assay system, Pharmacia Diag-
nositics, Milton Keans, UK).
Subjects completed a 100 mm cough Visual Analogue
Score (VAS) set at the bottom end by no cough and the top
end the worst cough ever. Patients were asked to mark
a cross at a point indicative of the severity of their cough
over the past 24 h. A change of >15 mm was regarded as
significant.2
Study design
Subjects had spirometry, cough VAS, sputum differential
cell count and a capsaicin cough challenge test at baseline
when they first presented to clinic. These tests were
repeated 7e10 years from diagnosis.
Analysis
C2 and C5 were log transformed prior to analysis to assume
a normal distribution. Correlations between variables were
analysed using Spearmans rank correlation coefficient for
non-parametric data. Statistical analysis was performed
using SPSS 18. The rate of FEV1 decline was calculated as
the total decline in FEV1 (calculated from a baseline FEV1
measurement and repeat FEV1 measurement 7e10 years
later) divided by the number of years between the
measurements.
Results
We identified 45 patients who were diagnosed with unex-
plained chronic cough out of a total of 286 patients with
cough seen between January 1998 and December 2001. Of
these patients 3 declined to take part in the study. Of the
remaining 42 patients (32 female), 12 declined to have
repeat airways assessment but agreed to complete a cough
VAS.
Patient characteristics are given in Table 1. The mean
(SD) duration of cough was 11.5 (4.5) years at the time of
their final assessment. Nine patients (21%) had organ
specific autoimmune disease (3 with hypothyroidism, 1 with
ulcerative colitis, 1 with coeliac disease, 1 with type 1
diabetes mellitus, 1 with vitiligo, 1 with pernicious anaemia
and 1 patient with hypothyroidism, vitiligo and pernicious
anaemia) and twenty (48%) had a peripheral blood lym-
phopaenia. Six (14%) patients had complete resolution of
symptoms; 10 (23%) patients showed no change in their
symptoms (change in VAS of <15 mm); 11 patients (25%)
had a significant (>15 mm) improvement in their cough
Table 1 Demographic data and study measurements at diagnosis and re-assessment.
Baseline Re-assessment
Number (females) 42 (32)
*Age at onset of cough 51(10)
*Duration of cough at final assessment (years) 11.5 (4.5)
*Percentage predicted FEV1 105 (15) 93.8 (15)
*FEV1/FVC 77 (5) 77 (11)
Sputum neutrophils (%) 49 (24) 61 (23)
ySputum eosinophils (%) 0.6 (0.7) 0.6 (0.7)
yC2 (Mmol/L) 2.4 (0.6) 1.3 (0.9)
yC5 (Mmol/L) 10.1 (0.9) 2.7 (0.8)
*Cough visual analogue scale (mm) 47 (24) 44 (29)
Percentage of patients with organ specific autoimmune disease (%) 10 (23)
Number of patients with a peripheral blood lymphocyte count of <1.5 (%) 20 (48)
* Expressed as mean (standard deviation) or y as geometric mean (log standard deviation). FEV1 Z forced expiratory volume in one
second. FEV1/FVC Z forced expiratory volume over one second divided by forced vital capacity. C2 Z concentration of capsaicin
required to induce 2 coughs, C5 Z concentration of capsaicin required to induce 5 coughs.
410 N. Yousaf et al.with a mean (95% CI) decrease in VAS of 31 mm (20, 42 mm);
and 14 patients (33%) had significant >10 mm worsening of
their symptoms (Fig. 1) with a mean (95% CI) increase in the
VAS score 35 mm (20, 50 mm). Repeat C2 and C5 were
available in 10 patients. There was no significant difference
in the change in these measures and no evidence that the
change differed in patients whose cough improved or not
(Table 1, Fig. 2).
Longitudinal spirometry data was available in 30
patients. The median (IQR) rate of FEV1 decline was 45 (25,
84) ml/year (Fig. 3). Four (13%) patients had an FEV1 rate of
decline of greater than 100 ml per year, seventeen (57%)
patients had an FEV1 decline of 30e100 ml per year, four
(13%) patients had and FEV1 change ranging from 1 to 29 ml
per year and 4 patients had an improvement in FEV1 of up
to 30 ml per year. Four (13%) patients developed a post-Figure 1 Change in cough as measured by a cough VAS over
a 7e10 year period.bronchodilator FEV1/FVC of less than 0.7. FEV1 decline
was similar in patients with persistent cough and those
whose cough improved. No other independent predictors of
FEV1 decline were identified. There were no independent
predictors of improvement in cough.
Discussion
This is the first longitudinal study of outcome in patients
with unexplained chronic cough. Our patient group was
similar to those described previously with a predominanceFigure 2 Capsaicin cough sensitivity over time.
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Figure 3 Annual rate of FEV1 decline.
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specific autoimmune disease and peripheral blood lym-
phopenia.7 Just over half of the patient in this series had
either no change or worsening of cough after more than
a decade, emphasising the potential long-term morbidly
associated unexplained chronic cough. We were unable to
identify predictors of persistence or improvement in cough.
Unexpectedly, patients with chronic cough had a decline in
FEV1 well above what would be expected in a population of
non-smoking patients of this age and a significant minority
developed COPD. Decline in FEV1 occurred independently
of changes in cough severity.
Our findings should be regarded as preliminary and
hypothesis generating rather than definitive as the pop-
ulation was small, not all participants consented to a full
follow up assessment, and the findings may have been
influenced by responder bias and regression to the mean.
Further work in larger and better characterised populations
is clearly necessary. However, the demonstration of a rapid
decline in FEV1 is consistent with earlier work by Birring
et al.8 They described a small cohort of older female non
smokers with cough and unexplained fixed airflow
obstruction in whom there was a high incidence of organ
specific autoimmune disease and peripheral blood lym-
phopaenia. Collectively, these studies suggest that rather
than being a benign condition, non-smokers with chronic
cough may develop significant airflow obstruction linked to
chronic cough and autoimmune disease.
The magnitude of the decline in FEV1 is striking and also
argues against a chance finding. The mean annual rate of
decline of FEV1 in non-smoking women and men of this age
is 25 ml/year and 29 ml/year.9 In patients with COPD the
rate of decline is 33 ml per year.10 This compares with
a median FEV1 decline of 44 ml per year in our population.
The over representation of autoimmune diseases in
patients with chronic cough is suggestive of common
aetiological factors. Polymorphisms of the gene encodingcytotoxic T-lymphocyte associated antigen 4 (CTLA4), an
inhibitor of regulatory T cell activity, are associated with
a number of autoimmune diseases including autoimmune
thyroid disease and type 1 diabetes mellitus.11,12 Recently
Zhu et al. have shown an association between several
CTLA4 polymorphisms and the chronic bronchitis phenotype
in patients with COPD.13 Further studies involving geno-
typing and perhaps involving direct small airway sampling
are needed in this patient group to further explore the
association with autoimmunity and to evaluate the patho-
logical changes in the airways and the mechanism of
decline in lung function. These studies may also help in
identifying a potential therapeutic target.
Birring described a cohort of patients with unexplained
chronic cough and a bronchoalveolar lavage (BAL)
lymphocytosis.14 Potentially the lymphopaenia seen in
patients with cough might be linked to the homing of
activated lymphocytes to the lung, as is the case in
sarcoidosis. We have previously suggested that aberrant
homing of activated lymphocytes from the primary site of
autoimmune or chronic infection related inflammation
might lead to airway inflammation and damage.15 This
might be expected to be most likely to occur when the
chronic inflammatory conditions involve organs that are
embryologically related to the lungs and it is notable that
conditions such as inflammatory bowel disease,16 chronic
hepatitis C infection,17 autoimmune thyroid disease,7,14
and Helicobacter pylori-induced gastritis18 have all been
linked to airway disease. Alternatively, it is well recog-
nised that many patients with chronic unexplained cough
describe a preceding viral infection and following this
develop a chronic cough. It may be that the lymphopenia
seen in this group of patients is as a result of a prior viral
infection. Furthermore, there is a strong associated with
lymphopenia and both systemic and organ specific auto-
immunity.15e17 Lymphopenia results in homeostatic
peripheral T cell expansion which is distinct from normal T
cell responses, and can result in T cell proliferation in
response to self-antigens, leading to the development of
organ specific auto-immune disease.18 It is possible that
the peripheral blood lymphopenia and the BAL lymphocy-
tosis are indicative of an airway specific autoimmune
process. The physiological, radiological and pathological
features of the airway disease seen in association with
chronic inflammatory disorders have not been extensively
investigated. It has been suggested that they are due to
a low grade obliterative bronchiolitis analogous to that
seen in chronic rejection in lung transplant recipients or
chronic graft vs. host disease in bone marrow transplant
recipients.15 Unexplained chronic cough is particularly
prevalent in menopausal women perhaps because CD-4
positive T-cell numbers increase in the lung at this time.19
In conclusion, we have shown that a small majority of
patients with unexplained chronic cough who consented to
a further assessment at least 7 years after the first have
persistent morbidity due to cough. Patients with unex-
plained chronic cough also had an abnormally rapid decline
in FEV1 and around 10% developed spirometric features of
COPD. Our findings raise the possibility that unexplained
chronic cough is due to a persistent damaging airway
process and suggest that this condition could be regarded as
a risk factor for developing COPD.
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